LDLR and metabolic syndrome: Perhaps individuals with persistent dyslipidemia have restoration of SREBP-mediated downregulation of LDLR with ERT without the expected concomitant reduction in de novo cholesterol biosynthesis, a dangerous point of inflection on a dyslipidemia curve.